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Abstract
Objectives: To understand the relation between risk genes for Alzheimer’s disease (AD) and their influence on biomarkers
for AD, we examined the association of AD in the Finnish cohort with single nucleotide polymorphisms (SNPs) from top
AlzGene loci, genome-wide association studies (GWAS), and candidate gene studies; and tested the correlation between
these SNPs and AD markers Ab1–42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF).
Methods: We tested 25 SNPs for genetic association with clinical AD in our cohort comprised of 890 AD patients and 701-
age matched healthy controls using logistic regression. For the correlational study with biomarkers, we tested 36 SNPs in a
subset of 222 AD patients with available CSF using mixed models. Statistical analyses were adjusted for age, gender and
APOE status. False discovery rate for multiple testing was applied. All participants were from academic hospital and research
institutions in Finland.
Results: APOE-e4, CLU rs11136000, and MS4A4A rs2304933 correlated with significantly decreased Ab1–42 (corrected
p,0.05). At an uncorrected p,0.05, PPP3R1 rs1868402 and MAPT rs2435211 were related with increased t-tau; while SORL1
rs73595277 and MAPT rs16940758, with increased p-tau. Only TOMM40 rs2075650 showed association with clinical AD after
adjusting for APOE-e4 (p = 0.007), but not after multiple test correction (p.0.05).
Conclusions: We provide evidence that APOE-e4, CLU and MS4A4A, which have been identified in GWAS to be associated
with AD, also significantly reduced CSF Ab1–42 in AD. None of the other AlzGene and GWAS loci showed significant effects
on CSF tau. The effects of other SNPs on CSF biomarkers and clinical AD diagnosis did not reach statistical significance. Our
findings suggest that APOE-e4, CLU and MS4A4A influence both AD risk and CSF Ab1–42.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease with a
complex etiology. Neuritic plaques mainly composed of aggregat-
ed b-amyloid (Ab) and neurofibrillary tangles (NFTs) resulting
from hyperphosporylated tau protein (p-tau) are pathological
hallmarks of AD [1]. Ab1–42 tends to aggregate more compared to
other Ab isoforms [2]. Total tau (t-tau) concentrations in
cerebrospinal fluid (CSF) have been suggested to indicate the
extent of neuronal damage, while p-tau levels reflected the
phosphorylated state of tau [3]. P-tau and t-tau levels signal
axonal degeneration [4,5]. In AD, the concentration of CSF Ab1–
42 is decreased, which is supposed to reflect sequestration of Ab1–42
in amyloid plaques in the brain [6], while t-tau and p-tau levels are
increased [1].
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The majority of AD cases have been reported to have a strong
genetic component [7]. The apolipoprotein E (APOE) e4 allele is
the strongest known genetic risk factor for AD. Other high-risk
genetic variants have been identified in genome-wide association
studies (GWAS) (for review, see [8]). In addition, previous studies
showed that a number of candidate genes correlated with Ab or
tau. However, the relation between these AD risk genes and AD
biomarkers remains ambiguous. With the exception of APOE and
translocase of outer mitochondrial membrane 40 homolog
(TOMM40), single nucleotide polymorphisms (SNPs) identified in
case-control GWAS with clinical AD as outcome have not been
replicated in GWAS with biomarkers as outcome [9].
In the study, we first investigated whether previously reported
genetic risk factors for AD were associated with AD risk in a
Finnish case-control cohort. Second, we tested in the AD group
the effects of these variants on the AD markers Ab1–42 and tau in
CSF. We selected SNPs from AlzGene and GWAS, and from
candidate genes that previously showed a relation with CSF Ab1–
42 and tau.
Materials and Methods
Study Population
The Finnish-AD is a multicenter cohort comprised of 890 AD
patients and 701 age-matched healthy controls from Kuopio,
Oulu, and Tampere in Finland. All patients were diagnosed with
probable AD according to the National Institute of Neurological
and Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA)
criteria [10]. AD patients with an early onset did not show
conclusive evidence of autosomal dominant transmission or
mutations in the amyloid precursor protein (APP), presenilin 1
(PSEN1), or presenilin 2 (PSEN2) genes. Control subjects had no
symptoms of cognitive impairment based on clinical interview and
neuropsychological examination. Of the 890 AD patients, 222
from Kuopio provided CSF for our study.
The Ethics Committee of the North-Savo Hospital District,
Kuopio Finland, approved the study. The physician and/or the
study nurse gave written information of the study and explained
the study protocol to the patient and caretaker if available. All
participants provided written informed consent. A next of kin,
caretakers or guardians consented on the behalf of participants
whose capacity to consent was compromised. In these cases also
the patient’s own opinion was asked and considered, and the
patient was recruited in the study only when he or she also agreed
with this. The ethics committee approved this informed consent
procedure.
Gene Selection
We selected genes based on their reported association with AD
or effect on CSF Ab and tau. We included the 10 ‘top results’ loci
from AlzGene, which is an online database providing meta-
analyses of published genetic association studies (for AlzGene top
results criteria, see [11]), and selected the most promising SNPs
from GWAS or other candidate gene studies. APOE, CR1, BIN1,
CD2AP, CLU, MS4A4E, MS4A6A, PICALM, ABCA7, and CD33
were from AlzGene (for gene names, see Table S1). Analyses with
APOE alone were performed for reference purposes, as APOE is an
established susceptibility gene for sporadic AD [11–13]. Functions
of the AlzGene variants in relation to AD have been previously
described [9,14,15]. MS4A4A, EXOC3L2 and MTHFD1L have
been shown in GWAS to be associated with AD [16–18] but have
not been included in the AlzGene top list to date.
CYP19A and TOMM40 have been shown in GWAS with
biomarkers as outcome to be related to Ab, whereas EPC2 and
RELN were associated with tau [19–21]. CYP19A has also been
reported to increase AD risk [22].
The candidate genes we selected that have been studied in
relation to CSF biomarkers were ACE, IDE, MAPT, SORL1,
CYP46A1, BDNF, TF, PPP3R1, and another TOMM40 polymor-
phism. The effects of ACE, MAPT, SORL, and TOMM40 on Ab
and tau have been reported in a review (see [9]). PPP3R1 has been
correlated with increased p-tau [4]. BDNF was linked with
decreased total Ab while TF was related to decreased Ab1–42/
Ab1–40 ratio [23]. CYP46A1 has been associated with AD [24] and
correlated with Ab1–42 [25]. IDE has been reported to decrease
Ab1–42 in AD [26]. Moreover, it has been associated with AD risk
[27] and neuropathological Ab deposition [28].
Thirty-six SNPs in 25 genes were included in the analyses with
CSF biomarkers (Table S1). For the genetic association analyses,
we tested 25 genetic variants, excluding those in ABCA7, BIN1,
BDNF, CD2AP, CD33, CYP46, CLU, CR1, EPHA1, EXOC3L2,
MS4A4E andMS4A6A because these genes were previously studied
in the Finnish population and found to be associated with AD
either in the Finnish cohort alone or in multicenter GWAS
[16,24,29–31].
Genotyping
DNA was extracted from peripheral blood with EDTA and
amplified using polymerase chain reaction technique. DNA
samples were randomly placed on 384-well plates. Genotyping
using Sequenom iPlex platform (Sequenom, Hamburg, Germany)
was performed at University of Eastern Finland (UEF) in Kuopio.
Patients and controls were dichotomized as APOE-e4 carriers or
noncarriers.
Quality control procedures included using duplicates and
negative controls, filtering on individual sample and SNP call
rate, and testing whether the SNPs were in Hardy-Weinberg
equilibrium (HWE). Samples with an average call rate of 90%
were included. SNPs for the association analysis were in Hardy-
Weinberg equilibrium (p.0.001).
CSF Analysis
CSF was obtained through lumbar puncture performed at UEF
and the Kuopio University Hospital. Ab1–42, t-tau, and p-tau levels
were measured using commercially available INNOTEST en-
zyme-linked immunosorbent assays (ELISAs) (Innotest ß-amy-
loid(1–42), Innotest hTau Ag, and Innotest Phospho-tau(181P),
Innogenetics, Ghent, Belgium). All measurements were performed
at UEF.
The relation between SNPs and biomarkers was assessed only
for the AD group because the number of controls with available
CSF (n = 30) was too small to allow for meaningful analyses.
Statistical Analysis
SPSS version 19 (Chicago, IL, USA) was used for the statistical
analyses.
We performed power calculations for the genetic association
analyses [32]. Simulation analysis yielded more than 80% power
to achieve ,1.3–1.5 risk effect at p = 0.05, indicating that our
case-control sample size was sufficient to find moderate genetic
association with AD. The same risk effect for the false discovery
rate (FDR) corrected p= 0.005 yielded more than 50% power. For
quantitative trait association [33], we computed ,80% power for
an effect size of 60–70 pg/ml for the dominant model at p= 0.05
and 50% power at FDR corrected p= 0.005. Similarly for t-tau,
the effect size was 120–150 pg/ml and for p-tau 15–20 pg/ml for
Finnish AD Biomarker Study
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a power of 80% at p= 0.05 and 50% when FDR corrected
(p = 0.005).
Genetic association with AD was examined using Pearson chi-
square test for multiple group comparisons and binary logistic
regression for pairwise comparisons in univariate and multivariate
analysis adjusted for age, sex, and APOE-e4 status. The relation
between SNPs and biomarkers was assessed through mixed models
for multiple group comparisons and pairwise comparisons, with
correction for confounders. Normality was tested and assumed for
biomarkers.
For the binary association, we first performed an overall test
that provided information on genotype differences between cases
and controls, and multiple comparison tests. For the quantitative
association, we compared differences in mean biomarker values
between genotypes in the overall test. Based on genotype
frequencies, we opted to use a dominant model. Minor genotype
frequencies for both genetic association and CSF biomarker
analyses were 0–15% for 40–50% of the SNPs studied. This
reduces statistical power of a recessive model in most SNPs. All
analyses were first corrected for age and sex, and then repeated
with corrections for age, sex, and APOE-e4 status.
We used FDR correction for multiple testing, following the
method of Benjamini and Hochberg [34]. Corrections were based
on the number of SNPs tested and were performed separately for
binary and quantitative associations. Observed p-values were
ranked from smallest to largest. Adjusted p-values were succes-
sively computed in a step-up manner, starting from the second
largest p-value, as follows: observed p-value (total number of SNPs
tested/rank). Statistical significance was set at FDR adjusted
p,0.05.
Results
Characteristics of the Cohort
Table 1 shows the demographic characteristics of the partici-
pants. AD patients with available CSF did not differ from patients
without CSF in terms of onset age (p = 0.07) and Mini-Mental
State Examination [35] score (p = 0.77).
Genetic Association with AD
APOE conferred a significant AD risk of 6.30 times higher
among e4 allele carriers compared to noncarriers (p,0.0001,
Table 2). Age and gender did not affect the results (OR=6.25,
95% CI 5.22–8.15, p,0.0001).
TOMM40 rs157580, rs2075650, and rs8106922 indicated
association with AD risk in the univariate analyses (FDR
p,0.05). A protective effect was observed for G allele carriers of
rs157580 and rs8106922, and a risk effect for G allele carriers of
rs2075650. Only rs2075650 remained significant in the multivar-
iate analysis (unadjusted p,0.007) but did not pass FDR
correction (p.0.05).
Results forMAPT rs16940758 suggested no association with AD
(FDR adjusted p.0.05), although AD and control groups differed
in multiple comparison test. PPP3R1 rs1868402 and ACE rs4293
showed association with AD in multivariate analysis (unadjusted
p= 0.03 for rs1868402 and p= 0.01 for rs4293) but did not remain
significant after FDR adjustment. Overall and univariate analyses
with rs1868402 and rs4293 were not significant.
Effects of SNPS on CSF Ab1–42
APOE e4 allele carriers had significantly reduced CSF Ab1–42
(FDR adjusted p,0.05, Table 3). Apart from APOE, only CLU
significantly affected Ab1–42 among the AlzGene top loci. Carriers
of rs11136000 major allele (C, risk allele in AlzGene meta-analysis)
showed significantly decreased Ab1–42 (FDR adjusted p,0.05).
Of the SNPs identified in GWAS but not in the top AlzGene
loci, onlyMS4A4A correlated with Ab1–42. Minor allele carriers (A,
risk allele in GWAS) of rs2304933 showed significantly decreased
Ab1–42 levels (FDR adjusted p,0.05) compared to major allele (C)
carriers. The correlation was strengthened when corrected for
APOE-e4 status.
Decreased Ab1–42 levels among EXOC3L2 rs597668 minor
allele carriers (C, risk allele in GWAS) were observed (unadjusted
p= 0.02) but the correlation did not pass FDR filter (p.0.05).
Risk allele carriers of TOMM40 SNPs identified through GWAS
with biomarkers as outcome and through other candidate gene
studies had decreased Ab1–42 concentrations, but this was not
independent of APOE-e4 status (FDR adjusted p.0.05).
The rest of the SNPs did not exhibit conclusive effects on Ab1–42
concentrations.
Table 1. Characteristics of study participants.
Characteristics AD (N=890) Control (N=701) AD with CSF subgroup (n =222)
Age, mean (SD), y 69.8 (8.2)a 69.1 (6.2)b 69 (8)a
Female sex (%) 596 (67) 420 (60) 149 (67)
MMSE score, mean (SD) 19 (5) – 19 (6)
APOE e2/e3/e4 allelic distribution, % 2/53/45 4/80/16 –
Ab1–42 level (SD), pg/ml 735 (195)
c 443 (158)d
Phosphorylated tau level (SD), pg/ml 63 (26)e 84 (36)f
Total tau level (SD), pg/ml 311 (143)g 546 (269)h
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; N, n, sample size; SD, standard deviation; y, years; MMSE, Mini-Mental State Examination.
aOnset age.
bAge at examination.
cAvailable for 32 control subjects.
dAvailable for 222 AD patients.
eAvailable for 30 control subjects.
fAvailable for 151 AD patients.
gAvailable for 30 control subjects.
hAvailable for 159 AD patients.
doi:10.1371/journal.pone.0059676.t001
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Table 3. Effects of SNPs on CSF Ab1–42 in Alzheimer’s disease.
Chr, Gene SNP Genotypes Genotype, n
Mean (SD) Ab1–42 level, pg/ml,
per genotype p-value
Overall DM
Top AlzGene loci
1, CR1 rs6656401 GG/GA/AA 127/82/8 446(168)/443(142)/370(150) 0.48 (0.21) 0.82 (0.96)
2, BIN1 rs744373 TT/TC/CC 117/96/8 446(148)/440(161)/451(266) 0.97 (0.92) 0.94 (1.00)
2, BIN1 rs7561528 GG/GA/AA 99/97/25 447(152)/441(163)/443(173) 0.92 (0.71) 0.85 (0.77)
6, CD2AP rs9349407 GG/GC/CC 132/73/15 440(158)/450(152)/444(202) 0.97 (0.88) 0.84 (0.84)
8, CLU rs11136000 CC/CT/TT 75/112/32 400(116)/459(166)/497(194) 0.005 (0.01) 0.003a (0.005)
11, MS4A4E rs670139 AA/AC/CC 83/111/27 465(164)/436(155)/408(152) 0.18 (0.18) 0.13 (0.11)
11, MS4A6A rs610932 CC/CA/AA 116/87/17 447(153)/443(163)/410(176) 0.67 (0.74) 0.73 (0.51)
11, PICALM rs642949 TT/TC/CC 130/79/11 459(165)/432(148)/346(116) 0.07 (0.06) 0.12 (0.11)
11, PICALM rs3851179 GG/GA/AA 96/104/21 441(172)/453(149)/412(140) 0.52 (0.34) 0.95 (0.61)
19, ABCA7 rs37522461 CC/CG/GG 165/40/4 445(160)/446(159)/433(281) 0.99 (0.83) 0.90 (0.91)
19, CD33 rs3865444 GG/GT/TT 89/111/21 437(169)/448(155)/441(135) 0.87 (0.78) 0.65 (0.48)
19, APOE e2/e3/e4 50/111/61 532 (214)/441(136)/374 (95) ,0.001 ,0.001a
Selection GWAS SNPs not in AlzGene top
6, MTHFD1L rs11754661 GG/GA/AA 206/15/0 440(156)/490(189)/2c 0.20 (0.07) 0.20 (0.07)
11, MS4A4A rs2304933 CC/CA/AA 72/107/43 494(192)/428(133)/395(130) 0.002 (0.001) 0.001a (,0.0001)
11, MS4A4A rs4938933 TT/TC/CC 125/81/14 453(160)/435(152)/411(188) 0.60 (0.54) 0.41 (0.29)
19, EXOC3L2 rs597668 TT/TC/CC 97/98/24 472(192)/422(123)/423(129) 0.08 (0.56) 0.02 (0.28)
GWAS with biomarkers as outcome
2, EPC2 rs1374441 TT/TC/CC 119/85/15 440(172)/456(147)/411(109) 0.52 (0.38) 0.67 (0.58)
2, EPC2 rs4499362 CC/CT/TT 119/89/13 443(172)/445(140)/441(155) 0.98 (1.00) 0.96 (0.98)
15, CYP19A rs2899472 CC/CA/AA 132/79/11 454(163)/433(152)/378(122) 0.36 (0.22) 0.27 (0.19)
7, RELN rs429837 CC/CT/TT 111/83/27 439(137)/432(156)/498(230) 0.17 (0.21) 0.86 (0.79)
19, TOMM40 rs157580 AA/AG/GG 150/68/3 426(146)/476(175)/593(202) 0.04 (0.27) 0.02b (0.12)
19, TOMM40 rs2075650 AA/AG/GG 98/100/24 485(195)/418(112)/377(104) 0.002 (0.24) 0.001a(0.19)
Other candidate genes
2, PPP3R1 rs1868402 TT/TC/CC 121/75/18 447(173)/448(145)/418(131) 0.70 (0.56) 0.81 (0.53)
3, TF rs1049296 CC/CT/TT 176/40/4 449(165)/412(120)/539(146) 0.22 (0.37) 0.42 (0.42)
10, IDE rs1887922 TT/TC/CC 167/52/2 442(138)/437(196)/747(457) 0.03 (0.04) 0.82 (0.94)
11, BDNF rs6265 GG/GA/AA 128/45/3 430(156)/453(173)/432(142) 0.79 (0.62) 0.49 (0.35)
11, SORL1 rs2070045 TT/TG/GG 122/86/13 440(149)/453(166)/403(195) 0.58 (0.53) 0.89 (0.89)
11, SORL1 rs3824968 TT/TA/AA 58/66/35 438(130)/442(158)/457(206) 0.92 (0.87) 0.85 (0.68)
11, SORL1 rs73595277 CC/CG/GG 183/36/2 449(168)/421(102)/397(76) 0.65 (0.87) 0.35 (0.60)
14, CYP46a rs754203 TT/TC/CC 103/98/20 447(155)/467(160)/456(176) 0.85 (0.66) 0.72 (0.54)
17, ACE rs4293 AA/AG/GG 60/107/54 451(184)/451(154)/421(136) 0.26 (0.67) 0.56 (0.91)
17, MAPT rs16940758 CC/CT/TT 146/68/8 439(169)/449(141)/467(99) 0.90 (0.84) 0.68 (0.57)
17, MAPT rs2435211 CC/CT/TT 71/118/32 420(136)/456(167)/450(171) 0.29 (0.27) 0.12 (0.17)
17, MAPT rs1467967 AA/AG/GG 97/98/25 446(168)/451(161)/409(100) 0.58 (0.57) 0.81 (0.99)
17, MAPT rs7521 AA/AG/GG 62/112/46 419(105)/456(179)/449(165) 0.37 (0.33) 0.17 (0.14)
19, TOMM40 rs8106922 AA/AG/GG 113/91/18 417(126)/461(169)/520(236) 0.02 (0.75) 0.02b (0.55)
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; n, number of cases; SD, standard deviation; DM, dominant model; GWAS, genome-wide
association study.
Risk allele according to AlzGene meta-analyses or study source in bold and underscored. Information on risk allele was not available for all studies. P-values based on
mixed model.
analyses adjusted for age and gender; values in parenthesis () adjusted for age, gender and APOE-e4 status. Analyses testing APOE adjusted for age and gender. Results
for APOE are shown for comparative purposes.
aSignificant at false discovery rate corrected P,0.05.
bNo longer significant after false discovery rate correction.
cNo cerebrospinal fluid measured because none of the participants carried the rs11754661 AA genotype.
doi:10.1371/journal.pone.0059676.t003
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Effects of SNPs on CSF Tau
None of the SNPs from the top AlzGene loci significantly
correlated with CSF t-tau and p-tau. The strongest effect was for
PICALM rs642949 and t-tau (p = 0.06, adjusted for age, sex, and
APOE-e4 status), with increased t-tau levels among minor allele (C)
carriers (Table 4). APOE e4 allele carriers also showed a
nonsignificant increase in t-tau concentrations (p = 0.08).
None of the polymorphisms in other GWAS with clinical AD as
outcome were linked with t-tau and p-tau.
From GWAS SNPs with biomarker as outcome, none of the
results attained statistical significance. EPC2 rs1374441 and t-tau
showed the strongest effect. T-tau levels increased among minor
allele (C, risk allele in GWAS) carriers (p = 0.06, corrected for age,
sex, and APOE-e4 status).
Of the SNPs selected from other candidate genes, marginal
correlations at FDR unadjusted p,0.05 were obtained for
polymorphisms in PPP3R1, SORL1, and MAPT (Table 4). T-tau
levels increased among carriers of PPP3R1 rs1868402 major allele
(T, FDR adjusted p.0.05). The effect was strengthened when
corrected for APOE-e4 status.
SORL1 rs73595277 minor allele carriers (G) had increased p-tau
(FDR adjusted p.0.05). Effects of SORL1 slightly decreased with
APOE-e4 correction.
In MAPT, minor allele carriers of rs2435211 (T) had increased
t-tau levels (unadjusted p= 0.03) and minor allele carriers of
rs16940758 had increased p-tau levels (unadjusted p= 0.03).
Correcting for APOE-e4 status enhanced the effects. These results,
however, did not remain significant after FDR correction (adjusted
p.0.05 for both SNPs).
Discussion
We performed a case-control genetic association analysis of 25
AD risk variants and tested the effects of 36 risk variants on CSF
Ab1–42, t-tau, and p-tau in the AD group.
The allele frequencies of genes from AlzGene meta-analysis of
Caucasian ancestry were comparable with allele frequencies of
most SNPs in our study. Only APOE and TOMM40 showed
genetic association with AD. However, TOMM40 is in linkage
disequilibrium with APOE and did not exhibit an effect
independent of APOE, in accordance with recent evidence [36].
Of the AlzGene top loci, APOE and CLU correlated significantly
with decreased Ab1–42. Our result for APOE confirms previous
findings [37]. Other studies on CLU have not found the same
effect, which may be attributed to their smaller sample size
[38,39]. Consistent with GWAS findings, the minor allele of CLU
exerted a protective effect on AD risk [29], and on CSF Ab1–42 in
the Finnish cohort. CLU did not significantly affect tau. CLU binds
soluble Ab and plays a role in Ab clearance and aggregation [14],
which could partly explain why it primarily affected Ab.
PICALM affects Ab concentration in the brain through
endocytic processes. Rs3851179 has been reported to correlate
with CSF Ab1–42 in another study, the major allele (G) being the
risk allele [39]. In our cohort, we found no correlation between
rs3851179 and CSF markers. Instead, rs642949 minor allele
carriers (C) had decreased Ab1–42 and increased t-tau levels,
although these were not statistically significant. The C allele of
rs642949 has been reported to exert a risk effect in a case-control
study [40].
APOE and the other top AlzGene loci did not correlate with t-
tau and p-tau in our cohort.
Of the GWAS SNPs not in AlzGene top loci, MS4A4A showed
significant correlation with Ab1–42 but not with tau. This is a novel
finding. MS4A4A belongs to the MS4A cluster [18]. Not much is
known yet about MS4A4A rs2304933 but its effect on Ab1–42 is
consistent with our genetic association analysis results suggesting a
risk effect of the minor (A) allele. The mechanisms by which
MS4A4A affect CSF Ab1–42 levels need further investigation.
The decrease in Ab1–42 levels among C allele carriers of
EXOC3L2 rs597668 is interesting. Although not statistically
significant (FDR adjusted p.0.05), it conferred with a previous
study identifying the C allele as a risk allele in the Finnish
population [30]. The C allele has also been reported in another
study to promote AD progression [41].
Among GWAS SNPs with biomarker as outcome, TOMM40
SNPs correlated with CSF Ab1–42 but not with tau, which was
consistent with previous findings [19,20]. None of the TOMM40
SNPs remained significant after APOE correction.
The SNPs from candidate genes were not related to CSF Ab1–
42. For tau, the small effects we observed for variants in PPP3R1,
SORL1, and MAPT (unadjusted p,0.05) were suggestive of a
trend. PPP3R1 is a protein phosphatase and is the calcium binding
regulatory subunit of calcineurin [42]. Calcineurin is involved in
modulating tau phosphorylation [43]. A previous study found
PPP3R1 to correlate with p-tau [4]. In our cohort, we found an
effect on t-tau but the effect on p-tau was weaker. This difference
in results could partly be attributed to variability in population.
SORL1 binds to ApoE and plays a role in Ab1–42 production
[37]. Numerous SNPs in SORL1 have been studied in relation to
AD [44] and CSF biomarkers [37] but results so far have been
inconclusive [9]. One study found that rs3824968 in SORL1
significantly reduced Ab1–42 in AD [45] whereas another study
reported no correlation [46]. SORL1 appears to exert small effects
likely to be detected only in mega-analysis of pooled samples [47]
or in haplotypes [48]. In general, single loci in SORL1 did not
correlate with CSF Ab1–42 and tau [9]. Our result relating SORL
with p-tau may be due to chance.
MAPT codes for tau proteins. Aggregated hyperphosphorylated
tau proteins are a component of NFTs. Consistent with the
findings of another study, we foundMAPT to correlate with CSF t-
tau [49].
We noted a number of changes in the strength of correlation
when we corrected for APOE. TOMM40 was no longer associated
with AD and CSF Ab1–42. This confirms previous finding that
TOMM40 is in strong linkage disequilibrium with APOE. The
effect of EXOC3L2 on CSF Ab1–42 became nonsignificant. This
suggests that the effect was not independent of APOE. Due to our
small sample size, our result could also be a false positive. For the
other SNPs, we found no or minor changes on either AD risk or
correlation with CSF markers after APOE correction. This means
that the effects of these SNPs were independent of APOE, or that
our sample size was too small to detect interaction effects.
We found few SNP-related differences in CSF Ab because Ab
may already be strongly decreased in AD patients who were
already demented. The effect of genetic risk factors on amyloid
metabolism may be more evident in predementia stages. Of
interest is the weak correlation of MAPT and PPP3R1 with tau,
which confirms the role of these SNPs in tau metabolism. MAPT
and PPP3R1 also showed weak associations with clinical AD,
which suggest that they contribute to dementia risk. In the analyses
with biomarkers, none of the AlzGene or other GWAS SNPs were
related to tau, suggesting that these SNPs have no clear effect on
tau metabolism.
Our study had the unique design that we tested SNPs both for
genetic association in a clinical case-control design and for
correlation with CSF biomarkers. Another strength was the large
selection of high-risk SNPs identified by GWAS or other candidate
gene studies covering different possible pathophysiological path-
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ways. The small sample size remained a limitation. We had
sufficient power for finding moderate associations, but a larger
sample is needed for detecting the very small effect sizes of the
other SNPs studied, if these effects are present.
In conclusion, we provide evidence that APOE, CLU, and
MS4A4A, which have been identified in GWAS to be associated
with AD, also significantly affected CSF Ab1–42. To our
knowledge, ours is the first study to report on the correlation
between MS4A4A and CSF Ab1–42. None of the AD risk genes
studied showed significant effects on CSF tau. The nonsignificant
trends in PPP3R1 and MAPT in relation to tau may be due to our
small sample size rather than genuine lack of risk effects.
Collaboration on a larger scale is necessary to ascertain the effects
of the aforementioned SNPs and identify reliable genetic risk
variants for AD markers in CSF.
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Table S1 Genetic variants included in the study. We
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